hotspot -WSS

hotspot

author：comprehensive 2025-09-27 21:18:12 - browse：1

Three Wegovy injection pens in a row — first opinion coverage from STAT — Adobe

Novo Nordisk will test whether its GLP-1 drugs can help people with alcohol-associated liver disease, and, as part of that, will study if the treatments will change the amount of alcohol people drink.

This appears to be the first time the company is getting involved in research to see if the booming class of GLP-1 diabetes and obesity drugs can affect substance consumption, a question that academic researchers have been probing but the pharmaceutical industry has so far avoided.

The nine-month study will try three drugs alone and in combinations against placebo. The primary outcome being tested is change in liver scarring, or fibrosis, and one of the secondary outcomes is changes in alcohol consumption. The news of the study was first reported by Bloomberg.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Study on Amgen’s bispecific immunotherapy produces positive data

Wikipedia

WSS

Health tech investors get more selective as pandemic boom fades

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

STAT Summit: The economic case for universal basic health care

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

Cassava Sciences’ Alzheimer’s clinical trials should be halted

Travel bans should be based on evidence, not politics or fear

explore

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

leisure time

At least 13 dead in Texas as scorching temps continue

Discs beat pads, tampons for heavy menstrual flow, new study shows

Trump demands the U.S. pay no more for drugs than other countries … again

Why a market frenzy over new weight loss drugs defies logic

ChatGPT in medicine: STAT answers readers' burning questions

Hospitals use virtual reality to design more inclusive rooms for kids

Trump demands the U.S. pay no more for drugs than other countries … again

Roche drug slashes death risk in early

23andMe had bad news about my health. I wish a person had delivered it

Choosing scientific sides in the fight against Alzheimer's

leisure time

The problems with dementia villages

Choosing scientific sides in the fight against Alzheimer's

Why a market frenzy over new weight loss drugs defies logic

STAT Readout: Friday, Oct. 20 biotech updates

Sage's campaign to raise awareness of postpartum depression hits a nerve

How AI can help patients find reliable information about doctors

focus

Wikipedia

knowledge

Wikipedia